Optimization of trans-Resveratrol bioavailability for human therapy

Biochimie

Volumn 95, Issue 6, 2013, Pages 1233-1238

  Amiot, Marie Josephe ^a,b   Romier, Beatrice ^a   Anh Dao, Thi Mai ^a   Fanciullino, Raphaelle ^a   Ciccolini, Joseph ^a   Burcelin, Remy ^c   Pechere, Laurent ^d   Emond, Claude ^e,f   Savouret, Jean François ^g   Seree, Eric ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSERM   (France)

^c University Hospital of Toulouse   (France)

^d YVERY SARL   (France)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f BioSimulation Consulting Inc   (United States)

^g UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Bioavailability; Healthy volunteers; Pharmacokinetics; t Res; Toxicity; trans Resveratrol

Indexed keywords

GLUCURONIDE; RESVERATROL; TRANS RESVERATROL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SOLUBILITY; DRY POWDER; FEMALE; HUMAN; HUMAN EXPERIMENT; LIPID DIET; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PROCESS OPTIMIZATION; RASH; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANIMALS; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; CAPSULES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MICE; MIDDLE AGED; POWDERS; STILBENES;

MUS; RODENTIA;

EID: 84877729850     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2013.01.008     Document Type: Article

References (33)

1. S. Fulda Resveratrol and derivatives for the prevention and treatment of cancer Drug Discov. Today 15 2010 757 765
2. A. Bishayee, A.S. Darvesh, T. Politis, and R. McGory Resveratrol and liver disease: from bench to bedside and community Liver Int. 2010
3. C.C. Udenigwe, V.R. Ramprasath, R.E. Aluko, and P.J. Jones Potential of resveratrol in anticancer and anti-inflammatory therapy Nutr. Rev. 66 2008 445 454
4. S. Frojdo, C. Durand, and L. Pirola Metabolic effects of resveratrol in mammals-a link between improved insulin action and aging Curr. Aging Sci. 1 2008 145 151
5. C.F. Hung, Y.K. Lin, Z.R. Huang, and J.Y. Fang Delivery of resveratrol, a red wine polyphenol, from solutions and hydrogels via the skin Biol. Pharm. Bull. 31 2008 955 962
6. S. Das, and D.K. Das Anti-inflammatory responses of resveratrol Inflamm. Allergy Drug Targets 6 2007 168 173 (Pubitemid 47455785)
7. J.F. Savouret, A. Berdeaux, and R.F. Casper The aryl hydrocarbon receptor and its xenobiotic ligands: A fundamental trigger for cardiovascular diseases Nutr. Metab. Cardiovasc. Dis. 13 2003 104 113 (Pubitemid 38569449)
8. K. Garber A mid-life crisis for aging theory Nat. Biotechnol. 26 2008 371 374 (Pubitemid 351501795)
9. M.E. Juan, M. Maijo, and J.M. Planas Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC J. Pharm. Biomed. Anal. 51 2010 391 398
10. C.H. Cottart, V. Nivet-Antoine, C. Laguillier-Morizot, and J.L. Beaudeux Resveratrol bioavailability and toxicity in humans Mol. Nutr. Food Res. 54 2009 7 16
11. T. Walle, F. Hsieh, M.H. DeLegge, J.E. Oatis Jr., and U.K. Walle High absorption but very low bioavailability of oral resveratrol in humans Drug Metab. Dispos.: The Biol. Fate Chem. 32 2004 1377 1382 (Pubitemid 39564557)
12. R.F. Casper, M. Quesne, I.M. Rogers, T. Shirota, A. Jolivet, E. Milgrom, and J.F. Savouret Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity Mol. Pharmacol. 56 1999 784 790 (Pubitemid 29491181)
13. A. Conte, S. Pellegrini, and D. Tagliazucchi Effect of resveratrol and catechin on PC12 tyrosine kinase activities and their synergistic protection from beta-amyloid toxicity Drugs Exp. Clin. Res. 29 2003 243 255 (Pubitemid 38568631)
14. P. Saiko, A. Szakmary, W. Jaeger, and T. Szekeres Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat. Res. 658 2008 68 94 (Pubitemid 351172881)
15. A. Amri, J.C. Chaumeil, S. Sfar, and C. Charrueau Administration of resveratrol: what formulation solutions to bioavailability limitations? J. Control Release 158 2012 182 193
16. World Medical Association Declaration of Helsinki Ethical principles for medical research involving human subjects J. Int. Bioethique 15 2004 124 129
17. L. Almeida, M. Vaz-da-Silva, A. Falcao, E. Soares, R. Costa, A.I. Loureiro, C. Fernandes-Lopes, J.F. Rocha, T. Nunes, L. Wright, and P. Soares-da-Silva Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers Mol. Nutr. Food Res. 53 Suppl. 1 2009 S7 S15
18. V.A. Brown, K.R. Patel, M. Viskaduraki, J.A. Crowell, M. Perloff, T.D. Booth, G. Vasilinin, A. Sen, A.M. Schinas, G. Piccirilli, K. Brown, W.P. Steward, A.J. Gescher, and D.E. Brenner Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis Cancer Res. 70 2010 9003 9011
19. D. Wang, T. Hang, C. Wu, and W. Liu Identification of the major metabolites of resveratrol in rat urine by HPLC-MS/MS J. Chromatogr. 829 2005 97 106 (Pubitemid 41773470)
20. T.M. Dao, A. Waget, P. Klopp, M. Serino, C. Vachoux, L. Pechere, D.J. Drucker, S. Champion, S. Barthelemy, Y. Barra, R. Burcelin, and E. Seree Resveratrol increases glucose induced GLP-1 secretion in mice: A mechanism which contributes to the glycemic control PLoS One 6 2011 e20700
21. A.C. Santos, F. Veiga, and A.J. Ribeiro New delivery systems to improve the bioavailability of resveratrol Expert Opin. Drug Deliv. 8 2011 973 990
22. A. Gescher, and A. Li Wan Po Correlation of physicochemical properties with absorption and metabolism of some tricyclic drugs J. Pharm. Pharmacol. 30 1978 353 358 (Pubitemid 8350927)
23. D. Horter, and J.B. Dressman Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract Adv. Drug Deliv. Rev. 46 2001 75 87
24. J.L. Dorne, K. Walton, and A.G. Renwick Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: A review Food Chem. Toxicol. 43 2005 203 216 (Pubitemid 40037938)
25. C. Manach, A. Mazur, and A. Scalbert Polyphenols and prevention of cardiovascular diseases Curr. Opin. Lipidol. 16 2005 77 84 (Pubitemid 40333370)
26. R.A. King, and D.B. Bursill Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans Am. J. Clin. Nutr. 67 1998 867 872 (Pubitemid 28196660)
27. H.G. Xie, R.B. Kim, A.J. Wood, and C.M. Stein Molecular basis of ethnic differences in drug disposition and response Annu. Rev. Pharmacol. Toxicol. 41 2001 815 850 (Pubitemid 32385908)
28. T. Walle Bioavailability of resveratrol Ann. N. Y. Acad. Sci. 1215 2011 9 15
29. M. Miksits, K. Wlcek, M. Svoboda, O. Kunert, E. Haslinger, T. Thalhammer, T. Szekeres, and W. Jager Antitumor activity of resveratrol and its sulfated metabolites against human breast cancer cells Planta Med. 75 2009 1227 1230
30. M. Alkhalaf, A. El-Mowafy, W. Renno, O. Rachid, A. Ali, and R. Al-Attyiah Resveratrol-induced apoptosis in human breast cancer cells is mediated primarily through the caspase-3-dependent pathway Arch. Med. Res. 39 2008 162 168 (Pubitemid 350299620)
31. Y. Li, J. Liu, X. Liu, K. Xing, Y. Wang, F. Li, and L. Yao Resveratrol-induced cell inhibition of growth and apoptosis in MCF7 human breast cancer cells are associated with modulation of phosphorylated Akt and caspase-9 Appl. Biochem. Biotechnol. 135 2006 181 192
32. H. Nakagawa, Y. Kiyozuka, Y. Uemura, H. Senzaki, N. Shikata, K. Hioki, and A. Tsubura Resveratrol inhibits human breast cancer cell growth and may mitigate the effect of linoleic acid, a potent breast cancer cell stimulator J. Cancer Res. Clin. Oncol. 127 2001 258 264
33. K.R. Patel, V.A. Brown, D.J. Jones, R.G. Britton, D. Hemingway, A.S. Miller, K.P. West, T.D. Booth, M. Perloff, J.A. Crowell, D.E. Brenner, W.P. Steward, A.J. Gescher, and K. Brown Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients Cancer Res. 70 2010 7392 7399